Profile of secukinumab in the treatment of psoriasis: current perspectives

Figures & data

Table 1 Efficacy studies of secukinumab

	Study title	Total number of patients	Dosages studied	Primary results
Psoriasis, Phase II	Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis^Citation20	125	Four dose cohorts: 1×25 mg (n=29), 3×25 mg (n=26), 3×75 mg (n=21), 3×150 mg (n=27) SC at weeks 0, 4, and 8 Placebo SC (n=22) at weeks 0, 4, and 8	82% of the 3×150 mg and 57% of the 3×75 mg group versus 9% of the placebo group achieved PASI 75 by week 12
	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis^Citation21	404	Three 150 mg SC induction doses: single (week 0; n=66), early (weeks 0, 1, 2, 4; n=133) and monthly (weeks 0, 4, and 8; n=138 patients)	54.5% of early and 42% of monthly induction regimens versus 1.5% in placebo group achieved PASI 75 at week 12
			Matching placebo (dosing at weeks 0, 1, 2, 4, and 8)
Psoriasis, Phase III	Secukinumab in plaque psoriasis – results of two Phase III trials^Citation23	738 in ERASURE trial	ERASURE study: two secukinumab SC doses at 300 or 150 mg (once weekly for 5 weeks, then every 4 weeks) Matching placebo doses	ERASURE study: 81.6% of 300 mg secukinumab group, 71.6% of the 150 mg secukinumab group, and 4.5% of the placebo group achieved PASI 75 at week 12
	Secukinumab in plaque psoriasis – results of two Phase III trials^Citation23	1,306 in FIXTURE trial	FIXTURE study: same as ERASURE study plus SC etanercept 50 mg dose twice weekly for 12 weeks, then once weekly	FIXTURE study: 77.1% of the 300 mg secukinumab group, 67% of the 150 mg secukinumab group, 44% of the etanercept group, and 4.9% of the placebo group achieved PASI 75 by week 12
	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial^Citation26	676	Two treatment groups: secukinumab 300 mg or ustekinumab per label (45 mg for subjects <100 kg at baseline; 90 mg for subjects >100 kg at baseline	79.0% of secukinumab patients versus was superior to (57.6%) of ustekinumab patients achieved PASI 90 response at week 16 (P<0.0001)
Psoriasis, Phase III subanalysis	Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis^Citation25	87	Same as ERASURE study	82.8% of the 300 mg secukinumab group, 86.2% of the 150 mg secukinumab group, and 6.9% of the placebo group achieved PASI 75 by week 12
Psoriatic arthritis, Phase II	Efficacy and safety of secukinumab, a fully human anti-IL-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis^Citation28	42	Two 10 mg/kg IV doses 3 weeks apart (n=28)	39% of the secukinumab group versus 23% of the placebo group achieved ACR20 responses at week 6
			Two matching placebo doses 3 weeks apart (n=14)
Psoriatic arthritis, Phase III	Secukinumab inhibition of IL-17A in patients with psoriatic arthritis^Citation29	606	Three treatment groups: secukinumab 150 mg IV (10 mg/kg), 75 mg IV (10 mg/kg), or placebo. All treatment groups received either IV secukinumab or placebo doses at weeks 0, 2, and 4, followed by SC secukinumab or placebo	50% of patients in the secukinumab 150 mg group and 50.5% of patient in the secukinumab 75 mg group achieved ACR20 response rates at week 24 compared to only 17.3% of placebo patients (P<0.001)
	Secukinumab, a human anti-IL-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, Phase III trial^Citation30	397	3 dose cohorts: secukinumab SC 300, 150, or 75 mg once a week from baseline and then every 4 weeks from week 4	54% of the 300 mg group, 51% of the 150 mg group, and 29% of the 75 mg group versus 15% of placebo group achieved an ACR20 at week 24
			Matching placebo SC dosing

Abbreviations: SC, subcutaneous; PASI, psoriasis area and severity index score; IV, intravenous; ACR20, American College of Rheumatology response criteria; PsA, psoriatic arthritis.

Table 2 Common adverse effects of secukinumab treatment

Clinical studies	Most common adverse effects (% of total patients on secukinumab regimen during entire trial)
Langley et al^Citation23 (FIXTURE study)	Nasopharyngitis (24.6%)
	Headache (11.2%)
	Diarrhea (7.9%)
McInnes et al^Citation28	Nasopharyngitis (25.0%)
	Headache (21.4%)
	Neutropenia (21.4%)
	Nausea (14.3%)
	Dizziness (14.3%)
Rich et al^Citation21	Nasopharyngitis (16.1%)
	Neutropenia (6.3%)
	Headache (5.9%)
	Upper respiratory tract infection (4.2%)
Papp et al^Citation20	Nasopharyngitis (12.6%)
	Neutropenia (7.4%)
	Headache (4.9%)
	Pharyngitis (2.9%)
Ohtsuki et al^Citation25	Nasopharyngitis (33.7%)

PappKALangleyRGSigurgeirssonBEfficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyBr J Dermatol2013168241242123106107

 PubMed Web of Science ®Google Scholar

RichPSigurgeirssonBThaciDSecukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding studyBr J Dermatol2013168240241123362969

 PubMed Web of Science ®Google Scholar

LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392

 PubMed Web of Science ®Google Scholar

ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol201573340040926092291

 PubMed Web of Science ®Google Scholar

OhtsukiMMoritaAAbeMSecukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 studyJ Dermatol201441121039104625354738

 PubMed Web of Science ®Google Scholar

McInnesIBSieperJBraunJEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnn Rheum Dis201473234935623361084

 PubMed Web of Science ®Google Scholar

MeasePJMcInnesIBKirkhamBSecukinumab inhibition of interleukin-17a in patients with psoriatic arthritisN Engl J Med2015373141329133926422723

 PubMed Web of Science ®Google Scholar

McInnesIBMeasePJKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703

 PubMed Web of Science ®Google Scholar